Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.7165 EUR -2.18%
Market Cap: 487.4m EUR

Intrinsic Value

The intrinsic value of one PHARM stock under the Base Case scenario is 1.1305 EUR. Compared to the current market price of 0.7165 EUR, Pharming Group NV is Undervalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PHARM Intrinsic Value
1.1305 EUR
Undervaluation 37%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Pharming Group NV

PHARM
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for PHARM cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Pharming Group NV
AEX:PHARM
NL
Biotechnology
Market Cap
486.2m EUR
IPO
Jul 2, 1998
NL
Biotechnology
Market Cap
486.2m EUR
IPO
Jul 2, 1998
Price
€false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about PHARM?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Pharming Group NV
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharming Group NV

Current Assets 278.7m
Cash & Short-Term Investments 167.9m
Receivables 55.1m
Other Current Assets 55.7m
Non-Current Assets 122.1m
Long-Term Investments 4.2m
PP&E 24.1m
Intangibles 61m
Other Non-Current Assets 32.7m
Efficiency

Free Cash Flow Analysis
Pharming Group NV

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pharming Group NV

Revenue
297.2m USD
Cost of Revenue
-35.4m USD
Gross Profit
261.8m USD
Operating Expenses
-270.4m USD
Operating Income
-8.6m USD
Other Expenses
-2.4m USD
Net Income
-11m USD
Fundamental Scores

PHARM Profitability Score
Profitability Due Diligence

Pharming Group NV's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
43/100
Profitability
Score

Pharming Group NV's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

PHARM Solvency Score
Solvency Due Diligence

Pharming Group NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
50/100
Solvency
Score

Pharming Group NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PHARM Price Targets Summary
Pharming Group NV

There are no price targets for PHARM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Pharming Group NV
does not pay dividends
Shareholder Yield

Current shareholder yield for PHARM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PHARM Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one PHARM stock?

The intrinsic value of one PHARM stock under the Base Case scenario is 1.1305 EUR.

Is PHARM stock undervalued or overvalued?

Compared to the current market price of 0.7165 EUR, Pharming Group NV is Undervalued by 37%.

Back to Top